PMHNP Scope of Practice for ADHD in California

If you’re a psychiatrist or psychiatric nurse practitioner considering telehealth for ADHD treatment, you’re probably asking: Can I legally prescribe Adderall, Vyvanse, or other stimulants to patients I’ve never met in person?

The short answer in 2026: Yes, through at least the end of 2026 — but with important caveats around state scope of practice, DEA registration, and upcoming permanent rules.

Here’s what you need to know to practice confidently and compliantly.

The Federal Landscape: Extended Flexibilities Through 2026

Normally, the Ryan Haight Act requires an in-person medical evaluation before prescribing any Schedule II controlled substance (which includes stimulants like Adderall and Ritalin). For years, this made purely virtual ADHD treatment legally impossible unless the patient had already been seen in person.

COVID changed everything. In March 2020, the DEA waived the in-person exam requirement for controlled substances prescribed via telehealth, as long as the prescription served a legitimate medical purpose and was issued after a real-time audiovisual consultation.

That waiver is still in effect. In January 2026, the DEA and HHS announced their fourth extension of these telehealth flexibilities, now running through December 31, 2026. This means you can continue to initiate ADHD medication treatment via video visits without any prior in-person exam — both for Schedule II stimulants and other controlled substances.

What Comes After 2026?

The DEA is finalizing permanent telehealth prescribing rules. Based on their January 2025 announcement, the new framework will likely include:

• Telemedicine Special Registration: Providers who want to prescribe controlled substances to new patients via telehealth will need a special DEA registration (beyond their standard DEA number). This will come with requirements like mandatory nationwide PDMP checks and patient identity verification during video consults.

• Established Patient Exception: If you’ve seen a patient in person at least once (or they’ve been seen by another provider in your practice), the special registration requirements won’t apply — you can continue treating them via telehealth freely.

• Platform Registration: Telehealth companies themselves will need to register with the DEA, adding corporate-level oversight to prevent ‘pill mill’ operations.

The takeaway: start thinking about special registration now. Once these rules take effect (likely 2027), having that credential will be essential for maintaining your telehealth ADHD practice without disruption.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Reality Check

Federal law sets the floor, but states can add their own requirements — and they vary dramatically on two critical issues: scope of practice (especially for NPs) and telehealth prescribing restrictions.

California

The Rules:

• No state-level in-person exam requirement for prescribing via telehealth
• Telehealth evaluation explicitly satisfies California’s prescribing standards
• Must check CURES (state PDMP) before initial stimulant prescription and every 4 months for ongoing treatment

For NPs:California is transitioning to full practice authority. Experienced NPs (3 years/4,600 hours under physician collaboration) can now practice independently, including prescribing stimulants without supervision. By 2026, all qualifying NPs can achieve independent status. New grads still need supervising physicians initially.

Bottom Line: California is provider-friendly for telehealth ADHD care, but you must be fully licensed in CA (no shortcuts or compacts for physicians).

Texas

The Rules:

• Telehealth prescribing allowed for mental health conditions
• Mandatory electronic prescribing for all controlled substances
• PDMP checks recommended (though not legally mandated for stimulants like they are for opioids)

For NPs — The Big Restriction:Texas prohibits nurse practitioners and PAs from prescribing Schedule II controlled substances in outpatient settings. Period. The only exceptions are for hospitalized patients (≥24 hours), hospice care, or emergency department orders.

This means only physicians (MD/DO) can prescribe Adderall, Ritalin, or other stimulants for outpatient ADHD treatment in Texas. If you’re an NP practicing in Texas, you’ll need a physician collaborator to actually write the prescriptions.

Bottom Line: Texas welcomes physician telehealth but severely restricts NP autonomy for ADHD medications. Factor this into your practice model.

Florida

The Rules:Florida explicitly permits prescribing Schedule II controlled substances via telehealth for treatment of psychiatric disorders (which includes ADHD). This carve-out was written into law in 2019, making Florida one of the clearer states on this issue.

Out-of-state providers can register with Florida’s Department of Health for telehealth practice without obtaining a full FL license — and this registration allows prescribing ADHD medications under the psychiatric exception.

For NPs:Psychiatric NPs can prescribe stimulants without the 7-day supply limit that applies to other Schedule II prescriptions (Florida normally restricts APRNs to 7-day supplies). However, PMHNPs must work under a protocol agreement with a supervising psychiatrist — Florida doesn’t include psych NPs in its independent practice pathway.

Bottom Line: Florida is telehealth-friendly with clear legal permission for ADHD prescribing, but NPs need physician oversight. Must check E-FORCSE (state PDMP) before prescribing.

New York

The Rules:New York updated its controlled substance regulations in May 2025 to explicitly align with federal telehealth allowances. As long as federal law permits it, New York permits it.

Mandatory requirements:

• Check the state PMP (I-STOP registry) every time you prescribe a Schedule II stimulant
• Use electronic prescribing (no exceptions — NY has required this since 2016)
• Maintain documentation that meets the standard of care

For NPs:After 3,600 hours of practice, New York NPs can practice independently without a written collaborative agreement — including prescribing stimulants. New York is one of the more NP-friendly states.

Practical Advantage: New York allows up to 90-day supplies of stimulants for ADHD (instead of the usual 30-day limit) if you mark the prescription with condition code ‘B’ for ADHD. This reduces refill burden for stable patients.

Bottom Line: NY welcomes telehealth ADHD treatment with robust NP autonomy, but PDMP compliance is strictly enforced.

Pennsylvania

The Rules:Pennsylvania follows federal law without adding state-level barriers to telehealth prescribing. However, the state requires electronic prescribing for controlled substances and recommends (practically requires) checking the state PDMP before initial controlled substance prescriptions.

For NPs:Pennsylvania requires collaborative agreements between NPs and physicians. For Schedule II prescriptions (including stimulants):

• Limited to 30-day supply initially
• Any continuation beyond 30 days requires physician approval
• Physician must review NP’s Schedule II prescribing monthly

Bottom Line: Pennsylvania is straightforward for physicians but requires tighter physician oversight for NPs managing ADHD patients. PA is part of the Interstate Medical Licensure Compact (IMLC), making multi-state licensure easier for physicians.

Illinois

The Rules:Illinois permits telehealth prescribing under standard-of-care requirements, with no special state restrictions beyond federal law. Providers must obtain an Illinois Controlled Substance License in addition to DEA registration.

For NPs — Two-Tier System:

Under Collaboration:

• 30-day supply limit on Schedule II prescriptions
• Physician must approve any continuation beyond 30 days
• Monthly physician review required

Full Practice Authority (FPA):Illinois allows experienced NPs (4,000 hours + 250 CE hours) to achieve FPA status. FPA NPs can prescribe stimulants independently without physician consultation because stimulants are Schedule II non-narcotic substances (the consultation requirement only applies to narcotic Schedule IIs and benzodiazepines).

Bottom Line: Illinois offers a clear path to NP independence for ADHD care, making it attractive for experienced PMHNPs. Must check PDMP as best practice.

The Economics of Telehealth ADHD Practice

Let’s talk about what actually matters to your bottom line: patient acquisition cost and revenue potential.

The DIY Marketing Reality

If you’re building your own practice from scratch, acquiring a qualified psychiatric patient through traditional marketing channels typically costs $200-500+ when you account for:

• SEO investment: 6-12 months of consistent content, technical optimization, and often consultant/agency fees before seeing meaningful patient flow
• Google Ads: Mental health keywords run $15-40+ per click, and most clicks don’t convert. Realistic cost per booked patient: $200-400+
• Directory listings: Psychology Today, Zocdoc, and others charge monthly subscription fees ($100-300+) and you compete with hundreds of other providers on the same page. Zocdoc adds per-booking fees ($35-100+)
• Hidden costs: Staff time to handle and qualify leads, no-show rates from cold leads, failed campaign testing, ongoing optimization

Most solo providers don’t have the marketing expertise, budget, or patience for this. You’re spending $3,000-5,000/month on marketing with uncertain ROI while you wait for channels to mature.

The Platform Alternative

Platforms like Klarity Health use a pay-per-appointment model — similar to Zocdoc, but with pre-qualified patients already matched to your specialty and availability.

The value proposition:

• Zero upfront marketing spend — no monthly retainers or ad budgets
• Pre-qualified patient flow — patients are already screened and matched to your scope of practice
• No wasted spend — you only pay when a qualified patient actually books with you
• Built-in infrastructure — telehealth platform, scheduling, billing support included
• Both insurance and cash-pay patients — diversified revenue streams
• Complete schedule control — set your availability, work as much or little as you want

The economic reality: Instead of gambling $3,000-5,000/month on marketing that might work eventually, you pay a standard listing fee per new patient lead. That’s guaranteed ROI — you know your acquisition cost upfront, and you’re only paying for results.

For providers starting out or scaling, this removes the risk entirely. For established providers, it’s a way to fill schedule gaps without the overhead of maintaining marketing campaigns.

Critical Compliance Points for ADHD Telehealth

Regardless of where you practice, certain requirements are universal:

1. Proper Evaluation Standards

The DEA hasn’t lowered the bar for diagnosis. Your telehealth evaluation must be as thorough as an in-person visit:

• Full clinical interview via real-time video (audio-only doesn’t cut it for controlled substances, except in very limited circumstances)
• Documented DSM-5 criteria assessment
• Review of patient history, medication history, and potential contraindications
• Consideration of differential diagnoses

The temporary flexibilities are about where you conduct the evaluation, not how thoroughly you conduct it.

2. PDMP Checks Are Non-Negotiable

Most states now mandate checking the Prescription Drug Monitoring Program before prescribing controlled substances. Even where not legally required for stimulants, it’s the standard of care.

Document that you:

• Checked the PDMP before the initial prescription
• Reviewed the patient’s controlled substance history
• Found no concerning patterns (or, if present, how you addressed them)

This protects both your patient and your license.

3. Electronic Prescribing

Most states now require electronic prescribing for controlled substances. No paper prescriptions, no phone-in prescriptions. You need EPCS (Electronic Prescribing of Controlled Substances) capability integrated into your practice.

4. Documentation

Your notes should clearly establish:

• How you verified patient identity
• That the encounter was via audiovisual telehealth
• Your clinical reasoning for the ADHD diagnosis
• Why the specific medication and dose were appropriate
• That you reviewed risks, benefits, and monitoring plans

If audited, your documentation needs to demonstrate you met the standard of care and complied with federal/state rules.

Making the Transition to Telehealth ADHD Care

Here’s what you should do now:

For Psychiatrists (MD/DO):

1. Verify your state licenses cover the states where you want to practice (consider IMLC for multi-state expansion)
2. Ensure you have state-specific controlled substance licenses where required (Illinois, New York, etc.)
3. Set up EPCS and PDMP access for each state
4. Review your malpractice insurance for telehealth coverage
5. Prepare for DEA’s telemedicine special registration (likely required in 2027)

For Psychiatric NPs:

1. Check your state’s scope of practice requirements (collaboration agreements, supervision protocols)
2. If in restricted states (Texas, Pennsylvania, Illinois without FPA), establish physician collaboration before prescribing stimulants
3. Consider pursuing Full Practice Authority where available (California, Illinois, New York)
4. Ensure you meet any state-specific training requirements (pain management CE, controlled substance education)
5. Set up PDMP access and EPCS capability

For Everyone:

• Stay informed about DEA rule changes (subscribe to DEA updates or follow professional organizations like APA)
• Document meticulously — your notes should reflect the same level of care as in-person visits
• Consider joining a telehealth platform that handles patient acquisition and infrastructure while you focus on clinical care

The Bottom Line

Telehealth ADHD care is legally viable and economically attractive for providers — if you navigate the regulatory landscape correctly.

The extended federal flexibilities through 2026 give you runway to build or scale your telehealth practice. But don’t wait until the last minute to prepare for permanent rules. The providers who succeed will be those who:

1. Understand their state’s specific requirements (not just federal rules)
2. Establish compliant workflows (PDMP checks, EPCS, documentation)
3. Choose patient acquisition strategies that make economic sense (platforms vs. DIY marketing)
4. Stay ahead of regulatory changes (DEA special registration, state law updates)

The demand for ADHD treatment far exceeds supply. Telehealth removes geographic barriers and allows you to serve patients who would otherwise go untreated. The question isn’t whether telehealth ADHD care is viable — it’s whether you’ll position yourself to do it compliantly and profitably.

Ready to explore how Klarity Health handles the regulatory complexity and patient acquisition while you focus on providing excellent care? Join our provider network and start seeing qualified ADHD patients without the marketing gamble.

FAQ: ADHD Telehealth Prescribing

Can I prescribe Adderall via telehealth to a new patient I’ve never met in person?

Yes, through December 31, 2026, under the current DEA extension. You must conduct a thorough evaluation via real-time video, establish a legitimate diagnosis, and follow all state/federal prescribing requirements. After 2026, you’ll likely need a DEA Telemedicine Special Registration to continue prescribing to new patients without an in-person visit.

Do I need to be licensed in the state where my patient is located?

Yes. You must be licensed in the state where the patient is physically located during the telehealth visit. Some states offer telehealth registration for out-of-state providers (like Florida), and physicians may use the Interstate Medical Licensure Compact, but generally you need full state licensure.

What’s different about prescribing ADHD medications compared to other psychiatric medications?

ADHD medications (stimulants) are Schedule II controlled substances, making them subject to the Ryan Haight Act’s in-person exam requirement (currently waived federally through 2026). Non-controlled psychiatric medications (like SSRIs for depression) don’t face these restrictions — you can prescribe them via telehealth in any state where you’re licensed without special DEA rules.

Can nurse practitioners prescribe ADHD medications via telehealth?

It depends entirely on the state. In Texas, NPs cannot prescribe Schedule II stimulants in outpatient settings at all. In Pennsylvania and Illinois (without FPA), NPs can prescribe but with 30-day limits and physician oversight. In California, Florida, New York, and Illinois (with FPA), NPs have broader authority but may still need collaborative agreements depending on the state. Always check your specific state’s scope of practice laws.

Do I need to check the state PDMP before every ADHD medication prescription?

Most states legally require PDMP checks before prescribing controlled substances, either for every prescription or at least initially. Even where not strictly mandated for stimulants, checking the PDMP is the standard of care and protects you from disciplinary action. Document your PDMP review in the patient’s chart.

What happens if the DEA’s temporary flexibilities end and I haven’t prepared?

If you’re prescribing stimulants to patients you’ve never seen in person, you’ll need either: (1) the DEA Telemedicine Special Registration (once available), or (2) to conduct an in-person evaluation for any new patients before prescribing. Existing patients you’ve already established care with should be grandfathered under the ‘established patient’ exception. Don’t wait — start planning now for the transition.

Can I prescribe a 90-day supply of ADHD medication via telehealth?

It depends on state law. New York explicitly allows 90-day supplies for ADHD when properly coded. Most states default to 30-day supplies for Schedule II controlled substances. Some states restrict NPs to 30 days even if physicians can prescribe longer supplies. Check your state’s specific controlled substance regulations.

What if I want to practice telehealth in multiple states?

You’ll need licensure in each state where you treat patients. Physicians can use the Interstate Medical Licensure Compact to expedite licensing in participating states (20+ states as of 2026). You’ll also need DEA registration covering each state and must comply with each state’s PDMP, prescribing limits, and scope of practice rules. Platforms like Klarity can help navigate multi-state credentialing.

Sources and References

The following sources were consulted for this article. All regulatory details have been verified with the latest available information (primarily 2024-2026 sources):

1. DEA & HHS Press Release – Extension of Telemedicine Flexibilities Through 2026 (HHS.gov, January 2, 2026) – Official announcement of fourth extension of telehealth controlled substance prescribing flexibilities through December 31, 2026.

2. Healthcare Dive – ‘DEA, HHS extend telehealth controlled substance prescriptions flexibilities for fourth time’ (January 5, 2026) – Industry news coverage clarifying the extension applies to Schedule II-V drugs including ADHD medications.

3. DEA Press Release – ‘DEA Announces Three New Telemedicine Rules to Continue Open Access’ (dea.gov, January 16, 2025) – Official DEA summary of proposed permanent rules including Telemedicine Special Registration requirements and patient safeguards.

4. RxAgent Blog – ‘NP Prescriptive Authority by State (2026 Guide)’ (rxagent.co, December 28, 2025) – Comprehensive state-by-state analysis of nurse practitioner prescribing authority and scope of practice rules.

5. Texas Board of Nursing – APRN Practice FAQ (bon.texas.gov, current as of 2022) – Official guidance confirming Texas NPs cannot prescribe Schedule II controlled substances in outpatient settings.

6. Florida Statutes §456.47 – Telehealth law (leg.state.fl.us, effective July 2019) – Primary legal text establishing the psychiatric disorder exception for Schedule II telehealth prescribing.

7. Florida Statutes §464.012 – Nursing prescribing authority (leg.state.fl.us, updated 2016-2017) – Legal framework for APRN prescribing including limits and psychiatric nurse exceptions.

8. New York State Department of Health – Bureau of Narcotic Enforcement Guidance on Telehealth (ninthdistrict.org, May 2025) – Official guidance aligning New York state regulations with federal telehealth allowances for controlled substances.

9. Pennsylvania Code Title 49, Chapter 21 – CRNP Prescriptive Authority Regulations (pacodeandbulletin.gov, last amended December 2009, current through 2023) – Primary source for Pennsylvania NP prescribing limits including 30-day Schedule II supply restriction.

10. Illinois Administrative Code – Nurse Practice Act rules (ilga.gov, current through 2024, reflects 2017 law changes) – Legal framework for Illinois NP collaboration requirements, Full Practice Authority pathway, and Schedule II prescribing limits and physician consultation requirements.

Source:

• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,II%20to%20Schedule%20V%20drugs
• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,to%20hash%20out%20permanent%20regulations
• https://rxagent.co/blog/np-prescribing-authority#:~:text=Proposed%20DEA%20rules%20create%20a,for%20telemedicine%20prescribing
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://www.bon.texas.gov/faqpracticeaprn.asp.html#:~:text=there%20any%20settings%20other%20than,may%20prescribe%20Schedule%20II%20controlled
• https://www.ninthdistrict.org/home/2025/05/30/nysdoh-issues-guidance-on-prescribing-controlled-substances-via-telehealth#:~:text=as%20such%20terms%20are%20defined,the%20use%20of%20electronic%20prescribing
• https://www.pacodeandbulletin.gov/secure/pacode/data/049/chapter21/chap21toc.html#:~:text=,
• https://www.ilga.gov/agencies/JCAR/EntirePart?titlepart=06801300#:~:text=match%20at%20L5536%203,collaborating%20physician%20or%20podiatric%20physician
• https://rxagent.co/blog/np-prescribing-authority#:~:text=However%2C%20,3
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Prescribing%2C%20dispensing%2C%20or%20furnishing%20dangerous,the%20appropriate%20standard%20of%20care